Nanoform Finland Plc
April 12, 2022
07:00 p.m. Finnish time / 06:00 p.m. Swedish time
Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc
Nanoform Finland Plc’s (the “Company” or “Nanoform“) Board of Directors held its constitutive meeting on April 12, 2022.
The meeting elected the following persons to the Audit and Compensation Committee of the Board of Directors of the Company: Miguel Calado (chairperson), Jeanne Thoma (ordinary member) and Mads Laustsen (ordinary member). The Audit and Compensation Committee is a permanent committee of the Board of Directors and acts in accordance with its charter as adopted by the Board of Directors.
For further information, please contact:
+358 50 353 040
For investor relations queries, please contact:
Henri von Haartman
Director of Investor Relations
+46 7686 650 11
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The Company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services. Nanoform’s capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806. For more information please visit http://www.nanoform.com